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Effects of Extracellular Matrix Density and Mesenchymal
Stem Cells on Neovascularization In Vivo
Ekaterina Kniazeva, M.S.,1 Suraj Kachgal, M.S.,1,2 and Andrew J. Putnam, Ph.D.2
Aberrant angiogenesis is common to a variety of diseases in which alterations in tissue mechanical properties
also occur. A fundamental understanding of the interdependence of angiogenesis and tissue structural prop-
erties may enhance the development of therapeutic strategies. We previously established that increasing ex-
tracellular matrix density inhibits capillary morphogenesis in three-dimensional tissues in vitro, and that
addition of human mesenchymal stem cells (MSCs) partially rescues a healthy angiogenic phenotype. This
study’s goal was to investigate if these effects can be recapitulated in vivo. Human umbilical vein endothelial
cells, MSCs, or a mixture of both was suspended in fibrin gel precursor solutions of 5, 10, and 15 mg/mL
concentrations and injected subcutaneously into SCID mice. Neovascularization was assessed in tissue con-
structs retrieved at 3, 7, and 21 days by quantifying vessel numbers, perfusion, thickness, maturity, and peri-
vascular collagen deposition. The data show that changing extracellular matrix density inhibits capillary
morphogenesis in vivo in a manner consistent with that observed in vitro. Delivery of both human umbilical vein
endothelial cells and MSCs produced more robust and mature vessels than delivery of either cell type alone in all
tissue concentrations.
Introduction
Anumber of pathologies are characterized by inade-quate blood vessel growth and, consequently, insuffi-
cient nutrient supply to adjacent tissues. Therapeutic
angiogenesis via gene, protein, or cell delivery attempts to
combat this insufficiency by promoting neovascularization.1–4
Understanding the fundamental role of the extracellular ma-
trix (ECM) as a physical barrier to neovascularization may
enhance efforts to develop new approaches that promote
healthy and abundant vessel formation. A number of studies
have demonstrated that ECM density and mechanical prop-
erties play significant roles in regulating capillary morpho-
genesis in vitro. On two-dimensional (2D) culture substrates,
in vitro studies provide evidence that ECM ligand density can
control growth and morphology of capillary formation5 and
that mechanical cues impact tubulogenesis.6–8
In three-dimensional (3D) tissues, our lab and others have
shown that angiogenic processes in vitro may also depend on
mechanical properties of the surrounding interstitial matrix.
To investigate the contributions of tissue dimensionality and
mechanical properties, we previously adopted a fibrin-based
model of angiogenesis, first described by Nehls and Drenc-
khahn.9 In this model system, human umbilical vein endo-
thelial cells (HUVECs) form capillary-like structures in 3D
when cocultured with a supporting mesenchymal cell type,
such as normal human lung fibroblasts10 or bone-marrow-
derived mesenchymal stem cells (MSCs),11 both of which
secrete proangiogenic factors. In our prior studies, we dem-
onstrated that when the mesenchymal support cells were
cultured on top of the fibrin gel, a fixed distance away from
the HUVEC-coated microcarrier beads, increasing ECM
density significantly inhibited angiogenic sprouting and the
formation of capillary vessels in vitro.10–12 Mechanistically,
the inhibition caused by elevated ECM density is partially
related to the HUVECs’ inability to upregulate key matrix
metalloproteinases (MMPs), including MMP-2, MMP-9, and
MT1-MMP, which are necessary for successful remodeling of
the fibrin matrix. In addition, increased ECM density sig-
nificantly impeded diffusive transport.10 However, when
either normal human lung fibroblasts or MSCs were dis-
tributed within the hydrogel, they delivered proangiogenic
factors closer to the HUVECs, adopted a pericyte-like phe-
notype, and improved the angiogenic phenotype of the
HUVECs even in denser matrices.11,13
On the basis of our prior in vitro results, the primary ob-
jective of this study was to investigate the influence of ECM
density on capillary formation in vivo, and to assess the
ability of MSCs to stimulate functional vessels within dense
3D fibrin matrices in vivo. To accomplish this goal, fibrin gel
precursor solutions of varied protein concentrations of 5, 10,
or 15 mg/mL containing mixtures of HUVECs and/or MSCs
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were injected subcutaneously in SCID mice. Tissue con-
structs were retrieved at various time points, and the en-
gineered blood vessels present within tissue sections were
then evaluated in terms of quantity, perfusion, thickness,
stimulation of collagen production, and MSC differentiation
toward a smooth muscle cell phenotype. A definitive rela-
tionship between tissue density and capillary morphogenesis
in vivo was identified, and the ability of MSCs to support
formation of more functional and mature capillary networks,
regardless of tissue density, was demonstrated.
Materials and Methods
Cell culture
Human MSCs from human bone marrow (Lonza, Walk-
ersville, MD) were cultured in Dulbecco’s modified Eagle’s
medium (Sigma-Aldrich, St. Louis, MO) supplemented with
10% fetal bovine serum (Mediatech, Manassas, VA), 1%
penicillin/streptomycin (Mediatech), and 0.5% gentamicin
(Invitrogen, Carlsbad, CA) at 378C, 5% CO2 and used up to
passage 13. HUVECs were isolated from fresh umbilical
cords as described previously,14 cultured in fully supple-
mented endothelial growth medium (EGM-2; Lonza), and
used at passage 2. The medium was changed three times per
week, and cells were harvested at 80% confluency via tryp-
sin-EDTA (Mediatech) treatment.
Tissue construct implantation and retrieval
Animal procedures were performed in accordance with
NIH guidelines for laboratory animal usage following a
protocol approved by UC Irvine’s Institutional Animal Care
and Use Committee (IACUC). C.B-17/SCID male mice (Ta-
conic, Hudson, NY) aged 8 weeks were used for all experi-
ments. A prepared anesthetic/analgesic cocktail of ketamine
(95 mg/kg), xylazine (9.5 mg/kg), and buprenorphine
(0.059 mg/kg) (Western Medical Supply, Arcadia, CA) was
delivered via an intraperitoneal injection. The dorsal area of
each animal was subsequently shaved and sterilized with
betadine (Thermo Fisher Scientific, Fremont, CA) before in-
jection of the implant solution.
Fibrinogen (Sigma-Aldrich) solutions of 5, 10, and 15 mg/
mL concentrations were prepared in serum-free EGM-2 and
sterile filtered. Mixtures of cells necessary for implant con-
structs were spun down for 5 min at 200 g and re-suspended
in appropriate fibrinogen solutions at concentration of 1
million cells per 100 mL of solution. Just before injection, 5%
fetal bovine serum and 6mL of a thrombin (Sigma-Aldrich)
solution (50 U/mL) were added to 300 mL of the fibrinogen
solution and immediately injected subcutaneously on the
dorsal surface of the SCID mouse, two implants per animal.
While the implant polymerized, the animal was kept sta-
tionary for 5 min and subsequently placed in the recov-
ery cage. Testing conditions for fibrin implants included
triplicates of acellular, MSC only, HUVEC only, and MSC/
HUVEC cell mixture conditions in varied fibrin concentra-
tions of 5, 10, and 15 mg/mL, which were retrieved at 3, 7,
and 21 days, amounting to a total of 54 mice or 108 samples
(Table 1). At each retrieval time point, the animals were
euthanized and implants including surrounding skin and
muscle layers surgically removed.
Immunohistochemical explant processing
Explants were first fixed in 10% formalin solution over-
night, transferred to PBS solution, and then forwarded to
AML Laboratories (Rosedale, MD) for paraffin embedding
and sectioning. Five-micrometer sections were then depar-
affinized, rehydrated, and incubated in Target Retrieval so-
lution (Dako, Carpinteria, CA) for 25 min at 988C.
Immunohistochemical staining was performed with Dako
EnVision System-HRP (DAB) kit. Overnight incubation
using anti-human CD31 primary antibody diluted at 1:50
(Dako) or anti-human calponin at 1:50 dilution (Santa Cruz
Biotechnology, Santa Cruz, CA) was followed by treatment
with HRP-conjugated anti-mouse secondary antibody pro-
vided in the kit, and hematoxylin and eosin counterstain.
Negative controls involving staining with the secondary
antibody alone were generated for all samples to rule out the
possibility of nonspecific staining. All sections were also
stained using a trichrome kit (ScyTek Laboratories, Logan,
UT) according to the provided protocol.
Imaging and statistics
Stained tissue sections were imaged using a Nikon Eclipse
E800 microscope system at 400magnification. All digital
images obtained were numerically coded and all identifiable
markers removed to blind the researchers during the counting
and measuring procedures. For each histomorphometry met-
ric, 10 randomly selected fields of view were analyzed within
the fibrin implant on each section. Data from these 10 ran-
domly selected fields of view were compiled for each of three
independent explanted samples for each condition tested. The
resulting data reported represent mean standard deviation
(n¼ 3, with 10 images per sample), and were statistically an-
alyzed and represented using KaleidaGraph (Synergy Soft-
ware). A one-way analysis of variance was performed to
obtain statistical significance comparisons among data sets.
Statistical significance was assumed when p< 0.05. To facili-
tate understanding and interpretation of the data, and to more
easily observe different statistical comparisons, the resulting
figures portray the same data sets in two different ways: as a
function of both fibrin concentration and cell condition.
Table 1. Summary of Experimental Conditions
Cell type Acellular HUVECs MSCs HUVECsþ MSCs
5 mg/mL fibrin — 3 million/300 mL gel 3 million/300mL gel 1.5þ1.5 million/300 mL gel
10 mg/mL fibrin — 3 million/300 mL gel 3 million/300mL gel 1.5þ1.5 million/300 mL gel
15 mg/mL fibrin — 3 million/300 mL gel 3 million/300mL gel 1.5þ1.5 million/300 mL gel
HUVECs, human umbilical vein endothelial cells; MSCs, mesenchymal stem cells.
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Results
Lumen formation and quantification
of baseline vascularization levels
To establish a baseline level for the total number of blood
vessel-like structures formed within the implants, implanted
tissues retrieved at specific time points were first evaluated
by quantifying the number of structures with clearly identi-
fiable lumens in each condition. The overall gross morphol-
ogy of a typical fibrin implant in the subcutaneous space is
shown in Figure 1A; examples of lumen-containing struc-
tures that were counted to generate quantitative data are
shown as well. A second exemplary explant (Fig. 1B) shows
the typical organization seen in these experiments, including
skin, muscle, and fatty layers of the mouse tissue sur-
rounding the fibrin implant (marked F on the image). While
the thickness of the explants decreased slightly over time,
this organization remained uniform for all conditions. Neo-
vessels were characterized by the presence of hollow lumen
structures (Fig. 1C), which were evaluated for all conditions
in these experiments. Baseline quantification of all lumen-
containing structures, excluding structures that appeared to
be cells coalescing together but which have not yet formed a
hollow lumen in these studies, is shown in Figure 2A–F.
Significantly higher levels of capillary structures were ob-
served in 5 mg/mL fibrin gel implants containing both
HUVECs and MSCs; however, in tissues fabricated from 10
and 15 mg/mL fibrin, implants containing HUVECs only
exhibited higher numbers of lumens than did those con-
taining both HUVECs and MSCs combined. In addition, the
total number of lumen-containing structures was higher in
lower ECM densities for all cell conditions. The overall size
of the implants decreased over time due to the degradation
of the fibrin hydrogels, a process previously shown to be
required for capillary morphogenesis.11,13 However, because
the data reported here represent total numbers of vessels per
field of view, rather than vessel density (i.e., numbers of
vessels per implant area), the shrinking size of the implants
did not impact the quantitative results.
It was also necessary to identify the total number of ves-
sels with clearly defined lumens that were formed by the
implanted human cells, as opposed to those formed by in-
filtrating mouse cells. To distinguish implanted cells, the
sections were stained with anti-human CD31 antibody,
which identified HUVECs within the tissues (Fig. 3). The
resulting sections were imaged and the total numbers of
human CD31-positive structures with clearly identifiable
lumens were counted. Quantification of these data supported
our previous observation that enhanced vessel formation
was achieved in fibrin gels of lower protein concentrations.
These data were evaluated only in implants containing
HUVECs or HUVECsþMSCs (Fig. 3A–E), as the implants
containing only MSCs (i.e., lacking HUVECs) did not exhibit
any positive human CD31 staining, as expected (data not
shown).
Vessel maturity evaluation via perfusion
and vessel diameter quantification
Once the baseline quantities of vessels formed by the im-
planted cell types were established, any differences in ma-
turity, phenotype, and functionality of these newly formed
vessels were characterized. To evaluate functionality of these
vessels, the numbers of vessel lumens perfused with red
FIG. 1. The methods to charac-
terize fibrin-based implants and
neovascularization are depicted.
(A) A compilation of images stit-
ched together reveals the gross
morphology of a typical fibrin
implant (left). Candidate vessel
structures identified by the pres-
ence of well-defined lumens
(arrowheads, right) were counted
to yield a quantitative metric of
vessel formation. Higher magnifi-
cation images show (B) typical
implant orientation relative to the
subcutaneous mouse tissue (F
identifies fibrin) and (C) examples
of lumen-containing structures
that were quantified. Color
images available online at
www.liebertonline.com/tea.
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blood cells were quantified. CD31-stained tissue constructs
formed using 5 mg/mL fibrin contained the highest numbers
of perfused vessels in all cell conditions, and codelivery of
HUVECs and MSCs led to the greatest number of perfused
vessels across all ECM densities (Fig. 4A–E). Implants con-
taining HUVECs alone or MSCs alone were similar in terms
of the number of perfused structures. However, gels con-
taining HUVECs alone exhibited more leaky vessels, marked
by the presence of red blood cells not confined within clearly
identifiable hollow lumens but rather dispersed throughout
the extracellular space (Fig. 4F, G, asterisks mark extravas-
cular red blood cells). Quantification of lumen diameters also
revealed larger vessels in coimplant conditions, ranging from
about 18 mm in 5 mg/mL fibrin gels down to 11 mm in 15 mg/
mL fibrin gels (Fig. 5A–F). Larger vessels were also pre-
dominantly present in all conditions in lower ECM densities
(Fig. 5G–I), supporting the argument that higher ECM den-
sity impedes vessel maturation.
Collagen deposition and MSC differentiation
into stabilizing pericytes
To further assess vessel development and stability, peri-
vascular collagen deposition, which identifies more mature
and well-supported vessels capable of producing their own
ECM, was assessed in histological sections. A trichrome stain
revealed higher collagen deposition around nascent vessel
structures in tissues fabricated with lower density fibrin gels,
as well as in coculture conditions in all ECM concentrations
(Fig. 6A–G). Tissue sections were also stained for human-
specific calponin, a marker of smooth muscle differentiation,
to determine if the implanted MSCs differentiated toward
a stabilizing pericyte phenotype around the nascent vessels.
Larger numbers of human calponin-positive structures
were observed in the lower density fibrin gels (Fig. 7A–C),
and were also more prevalent in implants containing both
HUVECs and MSCs (Fig. 7D, E).
Discussion
This study explored the relationship between ECM den-
sity and capillary morphogenesis in vivo, and examined the
potential of MSCs to promote vessel development in fibrin
implants of increasing density. In previous studies using a
3D fibrin-based in vitro model, we demonstrated that capil-
lary morphogenesis was significantly reduced by increasing
ECM density, and that it could be partially restored by dis-
tributing MSCs throughout the tissue.11 This suggested a
FIG. 2. Quantification of the numbers of lumen-containing structures in tissue constructs containing (A) HUVECs only, (B)
MSCs only, or (C) HUVECsþMSCs in 5 (O), 10 (), and 15 mg/mL (&) fibrin-based implants. The same data are also
represented for (D) 5 mg/mL fibrin, (E) 10 mg/mL fibrin, (F) 15 mg/mL fibrin as a function of the cellular conditions, with
HUVECs alone (O), MSCs alone (), or HUVECsþMSCs (&) at days 3, 7, and 21. For panels (A–C), the star symbol ( )
denotes a statistically significant relationship ( p< 0.05) between each data set at day 21; for panels (D–F), indicates a
statistically significant relationship ( p< 0.05) between the HUVEC-only condition (O) and the other two cell conditions at day
21. HUVECs, human umbilical vein endothelial cells; MSCs, mesenchymal stem cells.
908 KNIAZEVA ET AL.
means to overcome restrictions on the diffusive transport of
large macromolecules imposed by elevated matrix density.10
Changes in fibrin concentration simultaneously influence
ECM mechanical properties,11 adhesive ligand density, and
proteolytic sensitivity, all of which could act as instructive
cues that regulate capillary morphogenesis. Nevertheless,
whether the ECM’s effects on capillary morphogenesis are
chemical, mechanical, or both, the relevance of these prior
in vitro observations for vascularization in vivo remained
unclear, and motivated this study. The important contribu-
tions of the current study are the demonstration that elevated
fibrin matrix density inhibited the formation of vasculature
in vivo much as it does in vitro, and that this inhibition can be
partially remedied by codelivering MSCs with HUVECs.
With respect to the first contribution, the data presented
show that matrix density plays a critical role in regulating
neovascularization in vivo. A significant reduction in the total
numbers of lumen-containing structures was observed in 10
and 15 mg/mL fibrin tissues as compared to 5 mg/mL
samples for all conditions (Fig. 2). In addition, ECM density
was also found to regulate vessel perfusion (Fig. 4), size (Fig.
5), perivascular collagen deposition (Fig. 6), and MSC dif-
ferentiation (Fig. 7). We previously showed that the initiation
of capillary morphogenesis and the maintenance of vessel
networks in vitro depend on the ECM’s resistance to the ac-
tin–myosin contractile machinery of ECs,12 and it is possible
that a similar mechanism accounts for our in vivo findings.
Mammoto et al. recently reported that maximal levels of
capillary vessel formation were observed in vivo in Matrigel
substrates with an elastic modulus (E) of 800 Pa (when com-
pared to 700 and 900 Pa substrates).15 Rheological measure-
ments of our fibrin gels revealed shear elastic moduli (G’) of
132 11 Pa for 5 mg/mL gels, 532 37 Pa for 10 mg/mL gels,
and 1205 74 Pa for 15 mg/mL gels. However, because fibrin
is a complex viscoelastic material that exhibits nonlinear
strain-hardening behavior,16 direct comparisons with Matrigel
based on elastic moduli are inappropriate, and the micro-
structures of these two gels are significantly different.
Nevertheless, if we consider these materials as perfectly in-
compressible, which implies that 3G’<<E, it is noteworthy
that optimal neovascularization occurred in fibrin gels whose
mechanical properties were of the same order of magnitude as
the Matrigel substrates utilized by Mammoto et al.
With respect to the second contribution, our data show
that codelivery of HUVECs with MSCs was partially capable
of overcoming the inhibitory effects of elevated matrix den-
sity. This is evident when comparing the results between 10
and 15 mg/mL fibrin, where the differences in functional
neovascularization of coculture conditions are minimal de-
spite higher ECM density (Fig. 4C). However, the mere
presence of MSCs did not uniformly enhance the quantity of
new blood vessels formed across all fibrin concentrations.
FIG. 3. Vessel structures stained positive for human CD31 in tissue constructs comprised of (A) 5 mg/mL fibrin, (B) 10 mg/
mL fibrin, (C) 15 mg/mL fibrin with either HUVECs alone (O) or HUVECsþMSCs (). For panels (B and C), indicates
statistically significant differences between the two data sets at day 21 ( p< 0.05). Data are also presented as a function of
fibrin concentration (D) HUVECs only, (E) HUVECsþMSCs in 5 (O), 10 (), and 15 mg/mL (&) fibrin-based implants at days
3, 7, and 21; indicates a statistically significant difference ( p< 0.05) between 5 mg/mL and the other two fibrin concen-
trations at day 21. (F) A representative human CD31-stained construct at day 21 in 15 mg/mL fibrin with HUVECs only.
Color images available online at www.liebertonline.com/tea.
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While greater numbers of lumen-containing structures were
present in HUVEC-MSC coimplant conditions within 5 mg/
mL fibrin matrices by day 21 (Fig. 2D), 10 and 15 mg/mL
fibrin implants containing HUVECs alone yielded more
lumen-containing structures than did HUVEC-MSC coim-
plants (Fig. 2E, F). A simple explanation for this observation
is based on our rationale that it was important to maintain a
constant total number of cells (Table 1); therefore, the im-
plants containing both HUVECs and MSC have only half the
number of HUVECs present in the HUVEC-only implants
(Table 1). However, by looking at the data in Figure 3A–C,
we observe that codelivery of HUVECs and MSCs does not
FIG. 4. Quantification of the number of perfused vessels in fibrin-based CD31-stained constructs in (A) 5 mg/mL fibrin, (B)
10 mg/mL fibrin, (C) 15 mg/mL fibrin as a function of the cellular conditions with HUVECs alone (O), and HUVECsþMSCs
(&) gels. For panels (A and B), indicates a statistically significant difference ( p< 0.05) between the HUVECsþMSCs (&)
condition and HUVECs alone (O) condition at day 21. The same data are also represented for (D) HUVECs alone, and (E)
HUVECsþMSCs in 5 mg/mL fibrin (O), 10 mg/mL fibrin (), or 15 mg/mL fibrin (&) at days 3, 7, and 21. For panel (D),
indicates a statistically significant difference ( p< 0.05) between the 5 mg/mL fibrin (O) condition and 10 mg/mL fibrin ()
condition at day 21. For panel (E), indicates a statistically significant difference ( p< 0.05) between the 5 mg/mL fibrin (O)
condition relative to the other fibrin conditions at day 21. Representative histology images of perfused constructs at day 21 in
(F) 5 mg/mL fibrin implants containing HUVECsþMSCs and in (G) 5 mg/mL fibrin containing HUVECs alone; asterisks
mark extravascular red blood cells. Color images available online at www.liebertonline.com/tea.
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result in the formation of more human-derived vessels across
the range of fibrin concentrations investigated in this study.
The metric employed in Figure 3 is more restrictive and
specific to vessels derived from the implanted human cells
when compared to the metric used in Figure 2 (quantification
of total lumen-containing structures). Because the data in
Figure 2 may also account for vessels formed by invading
mouse cells, it is possible that the higher values in the
HUVECsþMSCs condition observed in 5 mg/mL gels
(Fig. 2D) may actually reflect increased recruitment of host
vessels. It is also possible that cooperation and cross-talk
between the two cell types were initially impeded in tissues
of higher ECM density. However, and perhaps most im-
portantly, delivery of both cell types always outperformed
delivery of a single cell type alone by day 21, regardless of
fibrin concentration, in terms of vessel functionality as as-
sessed by quantifying the number of perfused vessels (Fig.
4A–C). Since the data in Figure 4 represent the most re-
strictive metric (perfused vessels) relative to all those used in
the first three figures, we conclude that codelivery of HU-
VECs with MSCs always led to the generation of the most
functional vessels in all three fibrin formulations tested here.
The presence of MSCs led to the establishment of more
mature vessels as compared to single-cell-type conditions, as
demonstrated by the increased size of the perfused vessels
(Fig. 5), increased perivascular collagen deposition (Fig. 6),
and evidence of MSC differentiation toward stabilizing
pericytes expressing smooth muscle markers (Fig. 7).
FIG. 5. Vessel diameter quantification in tissue constructs containing (A) HUVECs only, (B) MSCs only, or (C) HUVECsþ
MSCs in 5 (O), 10 (), and 15 mg/mL (&) fibrin gels. In panel (A), indicates a statistically significant difference ( p< 0.05)
between 5 mg/mL fibrin (O) and 15 mg/mL fibrin (&) conditions at day 21; in panel (C), indicates a statistically significant
difference ( p< 0.05) between the 5 mg/mL condition (O) and the other two concentrations at day 21. The same data are also
represented for (D) 5 mg/mL fibrin, (E) 10 mg/mL fibrin, (F) 15 mg/mL fibrin as a function of the cellular conditions, with
HUVECs alone (O), MSCs alone (), or HUVECsþMSCs (&) at days 3, 7, and 21. In panel (D), indicates a statistically
significant difference ( p< 0.05) between HUVECsþMSCs (&) and the other two conditions at day 21. Representative images
on day 21 of capillary vessels formed by codelivery of HUVECsþMSCs in (G) 5, (H) 10, and (I) 15 mg/mL fibrin. Color
images available online at www.liebertonline.com/tea.
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Our findings regarding the beneficial effects of MSCs on
neovascularization are consistent with many previous re-
ports, and support the hypothesis that the presence of a
stromal or mesenchymal cell type capable of differentiating
into a pericyte or smooth muscle-like cell stabilizes new
vessels. For example, cotransplantation of ECs with 10T1/2
mesenchymal progenitor cells in 3D fibronectin-type I col-
lagen gels yielded stable, long-lasting, and functional blood
vessels in vivo.17 Many other studies reinforce the ability of
pericytes and other stromal cells to enhance neovascular-
FIG. 6. Perivascular collagen deposition around neovessels formed in tissue implants containing (A) HUVECs only, (B)
MSCs only, or (C) HUVECsþMSCs in 5 (O), 10 (), and 15 mg/mL (&) fibrin gels. In panels (A and B), denotes that the
differences between 5 mg/mL fibrin (O) and the other gel concentrations are statistically significant ( p< 0.05) at day 21, and
among all concentrations in (C). The same data are also represented for (D) 5 mg/mL fibrin, (E) 10 mg/mL fibrin, (F) 15 mg/
mL fibrin as a function of the cellular conditions, with HUVECs alone (O), MSCs alone (), or HUVECsþMSCs (&) at days 3,
7, and 21. In panel (D), indicates a statistically significant difference between the HUVECsþMSCs (&) and MSCs alone ()
conditions. In panel (E), implants containing HUVECsþMSCs (&) exhibit statistically significant differences ( p< 0.05) in
perivascular collagen deposition by day 21, and in (F), between HUVECsþMSCs (&) and HUVECs alone (O), and between
HUVECs alone (O) and MSC alone (). (G) A representative day 21 image from a 10 mg/mL fibrin implant containing both
cell types. Color images available online at www.liebertonline.com/tea.
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ization in vitro and in vivo,18–24 but the exact mechanisms
remain unclear. Inducing 10T1/2 cells to adopt a pericyte
phenotype with TGF-b stimulated an angiogenic program of
gene expression, with upregulation of several genes impli-
cated in angiogenesis, including VEGF, IL-6, VEGF-C, HB-
EGF, CTGF, tenascin C, integrin a5, and Eph receptor A2.19
MSCs can also secrete an array of proangiogenic factors,25
and their anatomic location in perivascular niches in vivo
provides an ideal location for these cells to facilitate tissue
repair.26,27 However, we have also shown that MSCs increase
the levels of ECM remodeling enzymes.11 Their strategic
periendothelial locations may facilitate ECM degradation
and stabilization of new vessels, without directly increasing
vessel quantity, via mechanisms that are distinct from fi-
broblasts and other cells that can also secrete proangiogenic
factors.13
Overall, by systematically varying the density of a fibrin-
based subcutaneous implant, our study has demonstrated
that ECM density regulates neovascularization in vivo. Co-
delivery of MSCs and ECs in vivo led to enhanced vessel
functionality and maturation, supporting the idea that de-
livering both cell types into ischemic tissues may restore
tissue perfusion better than delivery of either cell type alone.
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